Dextromethorphan/esbupropion - Axsome Therapeutics

Drug Profile

Dextromethorphan/esbupropion - Axsome Therapeutics

Alternative Names: AXS-09

Latest Information Update: 24 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Axsome Therapeutics
  • Class Morphinans; Propiophenones; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Nicotinic receptor antagonists; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I CNS disorders

Most Recent Events

  • 24 Apr 2018 Chemical structure information added
  • 26 Feb 2018 Adverse events and pharmacokinetics data from a phase I trial in CNS disorders released by Axsome Therapeutics
  • 25 Feb 2018 Phase-I clinical trials in CNS disorders (In volunteers) in USA (PO) before February 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top